Cargando…

Pulmonary arterial hypertension in systemic sclerosis—when criteria and pathobiology differ

Detalles Bibliográficos
Autores principales:	Andréasson, Kristofer, Rådegran, Göran, Brunnström, Hans, Wuttge, Dirk M, Hesselstrand, Roger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850066/ https://www.ncbi.nlm.nih.gov/pubmed/31608943 http://dx.doi.org/10.1093/rheumatology/kez474

Ejemplares similares

Circulating plasma microRNAs in systemic sclerosis-associated pulmonary arterial hypertension
por: Wuttge, Dirk M, et al.
Publicado: (2021)

Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation—a prospective, observational study
por: Andréasson, Kristofer, et al.
Publicado: (2020)

Health-related quality of life, treatment adherence and psychosocial support in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2018)

Coping, social support and information in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A 2-year retrospective cohort study
por: Ivarsson, Bodil, et al.
Publicado: (2018)

Perceptions of Received Information, Social Support, and Coping in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2014)

Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment
por: Hjalmarsson, Clara, et al.
Publicado: (2021)

Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension
por: Bouzina, Habib, et al.
Publicado: (2019)

Decreased biventricular longitudinal strain in patients with systemic sclerosis is mainly caused by pulmonary hypertension and not by systemic sclerosis per se
por: Lindholm, Anthony, et al.
Publicado: (2019)

Everyday life experiences of spouses of patients who suffer from pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2019)

Persistent elevation of fibrosis biomarker cartilage oligomeric matrix protein following hepatitis C virus eradication
por: Andréasson, Kristofer, et al.
Publicado: (2019)

Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2022)

Plasma TRAIL and ANXA1 in diagnosis and prognostication of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2023)

Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis—an exploratory study
por: Hamberg, Viggo, et al.
Publicado: (2023)

Underfilling decreases left ventricular function in pulmonary arterial hypertension
por: Sjögren, Hannah, et al.
Publicado: (2021)

Atrioventricular plane displacement and regional function to predict outcome in pulmonary arterial hypertension
por: Lindholm, Anthony, et al.
Publicado: (2022)

Longitudinal changes in risk status in pulmonary arterial hypertension
por: Bouzina, Habib, et al.
Publicado: (2020)

Risk assessment in pulmonary arterial hypertension: A step towards clinical implementation based on the 2022 ESC/ERS pulmonary hypertension guidelines
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Pulmonary blood density quantified by CMR is reduced in newly diagnosed systemic sclerosis, consistent with pulmonary arteriolar proliferation
por: Kanski, Mikael, et al.
Publicado: (2011)

Predicting mortality during long-term follow-up in pulmonary arterial hypertension
por: Kylhammar, David, et al.
Publicado: (2021)

Right atrial volume measured by cardiac magnetic resonance correlates with NT-ProBNP and invasive right atrial pressure in pulmonary hypertension, with and without systemic sclerosis
por: Gyllenhammar, Tom, et al.
Publicado: (2016)

Increased right atrial volume measured with cardiac magnetic resonance is associated with worse clinical outcome in patients with pre‐capillary pulmonary hypertension
por: Bredfelt, Anna, et al.
Publicado: (2018)

Airway resistance and reactance are affected in systemic sclerosis
por: Aronsson, David, et al.
Publicado: (2015)

Pulmonary blood volume indexed to lung volume is reduced in newly diagnosed systemic sclerosis compared to normals – a prospective clinical cardiovascular magnetic resonance study addressing pulmonary vascular changes
por: Kanski, Mikael, et al.
Publicado: (2013)

Risk assessment in pulmonary arterial hypertension patients with multiple comorbidities and/or advanced age—Where do we stand and what's next?
por: Ahmed, Abdulla, et al.
Publicado: (2023)

High frequency ultrasound of skin involvement in systemic sclerosis – a follow-up study
por: Hesselstrand, Roger, et al.
Publicado: (2015)

Pulmonary blood density in systemic sclerosis – a novel non-invasive measure of pulmonary arterial hypertension?
por: Kanski, Mikael, et al.
Publicado: (2009)

Multiple Manifestations of Systemic Sclerosis Affect Walk Distance
por: Andréasson, Kristofer, et al.
Publicado: (2021)

Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study
por: Hjalmarsson, Clara, et al.
Publicado: (2020)

Type III, IV, and VI Collagens Turnover in Systemic Sclerosis – a Longitudinal Study
por: Juhl, Pernille, et al.
Publicado: (2020)

Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled
por: Hemnes, Anna R., et al.
Publicado: (2017)

Faecal levels of calprotectin in systemic sclerosis are stable over time and are higher compared to primary Sjögren’s syndrome and rheumatoid arthritis
por: Andréasson, Kristofer, et al.
Publicado: (2014)

Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2019)

Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2021)

Myocardial perfusion using cardiac magnetic resonance: Evidence of decreased global myocardial perfusion in patients with systemic sclerosis with possible gender differences
por: Gyllenhammar, Tom, et al.
Publicado: (2016)

Decreased global myocardial perfusion at adenosine stress as a potential new biomarker for microvascular disease in systemic sclerosis: a magnetic resonance study
por: Gyllenhammar, Tom, et al.
Publicado: (2018)

Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension
por: Ahmed, Abdulla, et al.
Publicado: (2021)

Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation
por: Säleby, Joanna, et al.
Publicado: (2019)

Low plasma stem cell factor combined with high transforming growth factor-α identifies high-risk patients in pulmonary arterial hypertension
por: Bouzina, Habib, et al.
Publicado: (2018)

Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension
por: Kjellström, Barbro, et al.
Publicado: (2022)

Absence of fibromodulin affects matrix composition, collagen deposition and cell turnover in healthy and fibrotic lung parenchyma
por: Rydell-Törmänen, Kristina, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o3nbdf6ekbuuhg5aihl83gspv0